Patients with these diseases must meet specific requirements to receive CAR T-cell therapy including that their cancer does not respond to initial chemotherapy and relapses within 1 year or there is relapse after 2 previous lines of chemotherapy. 1,2 Regarding NHL, the FDA has approved CAR T-cell therapy to treat diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma and transformed lymphoma. The complete response rates for ALL are approximately 60% to 70%. The Karmanos team collaborated with leading cancer centers around the country on various pivotal clinical trials leading to the FDA approval of CAR T-cell therapy. The outcomes of CAR T-cell therapies have been remarkable, especially because most patients receiving this immunotherapy have faced difficulties in controlling their disease despite multiple rounds of chemotherapy. Cancers Show Promising CAR T Response Rates CAR T-cell therapy is at the cutting edge of treatments for certain cancers, wherein the patient’s T cells, an integral part of the immune system, are genetically modified to recognize and kill the cancer cells. The institute also continues to support research into new treatment indications for which CAR T-cell therapy could be used. Karmanos offers all approved CAR T-cell therapies for non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). The Multiple Myeloma and Amyloidosis Multidisciplinary Team (MDT), Bone Marrow and Stem Cell Transplant MDT, and the Hematologic Oncology MDT at Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, have helped drive many treatment advancements in cellular immune therapies for cancers. In recent years, cellular immune therapies such as chimeric antigen receptor (CAR) T-cell therapy have significantly improved response rates for various hematological malignancies.
0 kommentar(er)
